Welcome to our dedicated page for Balchem news (Ticker: BCPC), a resource for investors and traders seeking the latest updates and insights on Balchem stock.
Balchem Corporation (NASDAQ: BCPC) is a global specialty ingredient manufacturer for health and nutrition markets, and its news flow reflects this focus. Company press releases highlight the development, manufacture and marketing of specialty ingredients that improve and enhance the health and well-being of life on the planet, as well as financial and corporate updates relevant to investors and industry observers.
Visitors to this BCPC news page can review Balchem’s announcements on quarterly financial results, dividend declarations and participation in investor conferences. Recent releases have reported segment-level performance for its Human Nutrition & Health, Animal Nutrition & Health and Specialty Products segments, along with measures such as net sales, earnings from operations, adjusted EBITDA and free cash flow, as described in accompanying Form 8-K filings.
Balchem also issues news related to regulatory and trade developments that affect its markets. For example, the company joined another EU producer in welcoming European Union anti-dumping duties on choline chloride imports from China, emphasizing the importance of fair trade for the EU food and feed supply chain and for maintaining a healthy domestic choline chloride industry.
In addition, Balchem regularly announces its participation in conferences hosted by firms such as CJS Securities, Baird, H.C. Wainwright, Wells Fargo and others, where its leadership presents to the investment community. These updates provide insight into how the company communicates its strategy and segment performance to shareholders and analysts. Investors and researchers can use this news stream to follow Balchem’s financial reporting, capital allocation decisions such as dividends, and its commentary on market and regulatory conditions affecting its human nutrition, animal nutrition and specialty products businesses.
Balchem Corporation (NASDAQ: BCPC) will hold a conference call on February 24, 2023, at 11:00 AM ET to discuss its fourth quarter results. These results will be released before the market opens on the same day. The call will be hosted by Ted Harris (CEO) and Martin Bengtsson (CFO). Investors can join by dialing 1-877-407-8289, and the session will be available for replay until March 10, 2023. Balchem specializes in developing and marketing specialty ingredients across Human Nutrition, Animal Nutrition, and Specialty Products sectors, aiming to enhance health and well-being globally.
Summary not available.
Balchem Corporation (NASDAQ: BCPC) CFO Martin Bengtsson will present at the CJS Securities 23rd Annual "New Ideas for the New Year" Investor Conference on January 11, 2023, starting at 11:00 AM EST. The presentation will be accessible on Balchem's website post-conference. Balchem specializes in developing and marketing ingredients that enhance health and well-being across various industries, with three main segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Balchem Corporation (NASDAQ: BCPC) announced a dividend of $0.71 per share on December 5, 2022, marking a 10.9% increase from the previous year. This dividend will be paid on January 20, 2023, to shareholders on record as of December 27, 2022. The announcement signifies the fourteenth consecutive annual dividend increase, highlighting the company's robust financial performance and the Board's confidence in its long-term strategies.
Balchem Corporation (NASDAQ: BCPC) reported a net earnings increase to $25.2 million for Q3 2022, compared to $25.0 million in Q3 2021. Adjusted net earnings rose to $32.4 million, up 8% year-over-year, with adjusted EBITDA at $53.8 million, reflecting an 11.2% increase.
Net sales reached $244.3 million, a 23.4% increase driven by growth in all segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. The effective tax rate declined to 18.8%. Cash flows from operations were $41.6 million, with free cash flow at $26.8 million.
Balchem Corporation (NASDAQ: BCPC) will host a conference call on November 4, 2022, at 11:00 AM ET to discuss its third quarter results. The financial results will be released before market opening on the same day. Interested parties can join the call by dialing 1-877-407-8289 or 1-201-689-8341 locally. A replay will be available until November 18, 2022, using conference ID #13733850. Balchem focuses on developing specialty ingredients across three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Balchem Corporation (NASDAQ:BCPC) has announced its acquisition of Cardinal Associates Inc., known as Bergstrom Nutrition, a leading producer of methylsulfonylmethane (MSM) based in Vancouver, Washington. This strategic purchase enhances Balchem's product portfolio, particularly in joint health, sports nutrition, and beauty sectors. Bergstrom's OptiMSM® is recognized for its quality, holding a U.S. GRAS designation. The integration aims to accelerate growth and expand marketplace opportunities in Balchem's Human Nutrition and Health segment, aligning with its focus on longevity and performance.
Balchem Corporation (NASDAQ: BCPC) reported a strong second quarter for 2022, with net earnings of $29.8 million, up 31% from $22.7 million in Q2 2021. Adjusted net earnings rose to $34.4 million, reflecting a 13.3% increase year-over-year. Record net sales reached $236.7 million, marking a 17.0% growth, driven by Human, Animal, and Specialty Nutrition segments. The company completed the acquisition of Kappa Bioscience, enhancing its portfolio in the nutrition sector. Operational cash flow was robust at $48.2 million.
Balchem Corporation (NASDAQ: BCPC) will hold a conference call on July 29, 2022, at 11:00 AM ET to discuss its second quarter results, which will be published before market opening on the same day. CEO Ted Harris and CFO Martin Bengtsson will lead the call. Participants can access the conference by calling toll-free 1-877-407-8289. A replay will be available from two hours post-conclusion until August 12, 2022, using conference ID #13731403. For more information, visit www.balchem.com.
Balchem Corporation (NASDAQ:BCPC) has successfully completed its acquisition of Kappa Bioscience AS, a leading manufacturer of specialty vitamin K2, enhancing its portfolio in the human nutrition sector. This acquisition, initially announced on June 14, 2022, aims to capitalize on the growing demand for vitamin K2, which is vital for bone health, heart health, and immunity. Kappa's K2VITAL® is recognized for its purity and stability, backed by strong intellectual property and clinical research.